Access all of the content
Dr George Goshua (Yale University School of Medicine, New Haven, CT, USA) shares with us his insights into the role of endotheliopathy in the development of coagulopathy in patients with COVID-19.
1. How common is coagulopathy in COVID-19 infection and who is at greatest risk? (0:03)
2. What is known about the role of endotheliopathy in the development of coagulopathy in patients with COVID-19? (1:39)
3. What is the link between the inflammatory response to SARS-CoV-2 and endotheliopathy? (2:23)
4. What practical advice would you give to physicians managing coagulopathy in patients with COVID-19 in terms of laboratory monitoring and anticoagulant therapy management? (3:33)
5. What can be done to identify high-risk populations? (5:33)
Abstract LB2605, Endotheliopathy is Essential in COVID-19 Associated Coagulopathy, is available at EHA25 Virtual here.
Speaker disclosure: George Goshua has nothing to disclose in relation to this video interview.
Support: Interview and filming supported by Touch Medical Media.
Filmed at the Virtual Edition of the 25th European Hematology Association Annual Congress (EHA25 Virtual), June 2020.
COVID-19 = coronavirus disease 2019; SARS CoV-2 = severe acute respiratory syndrome coronavirus 2.
Share this Video
Related Videos In Haematology
Spero R Cataland, Rare Disease Day 2022: Acquired thrombotic thrombocytopenic purpura – Risks, complications and the impact on daily life
Dr Spero R Cataland (The Ohio State University, Wexner Medical Centre, Columbus, OH, USA) joins us for Rare Disease Day to discuss the importance of rapid diagnosis of acquired thrombotic thrombocytopenic purpura (aTTP), a rare blood disorder in which blood clots form in small blood vessels throughout the body. In this interview, Dr Cataland discusses […]
Steven Pipe, ASH 2020 – First Results from the HOPE-B Gene Therapy Trial
We had the pleasure to talk to Steven Pipe (University of Michigan, Ann Arbor, MI, USA) to discuss the use of gene therapy for the treatment of haemophilia B. The abstract ‘First Data from the Phase 3 HOPE-B Gene Therapy Trial: Efficacy and Safety of Etranacogene Dezaparvovec (AAV5-Padua hFIX variant; AMT-061) in Adults with Severe […]
Efstathios Kastritis, EHA 2020: CYBORD in Amyloidosis and The ANDROMEDA Study
touchONCOLOGY joins Dr Efstathios Kastritis (Department of Clinical Therapeutics, National and Kapodistrian University of Athens, School of Medicine, Athens, Greece) at EHA25 Virtual to discuss the ANDROMEDA study (NCT03201965), and the efficacy and safety of daratumumab in combination with CYBORD for the treatment of newly-diagnosed light chain amyloidosis. Questions: What are the major therapeutic […]
Journal articles and more to your inbox
Get the latest clinical insights from touchONCOLOGYSign me up!